Transcatheter Heart Valve Replacement Market to Reach US$24.07 Billion by 2034 Driven by Rising Cardiovascular Disease Burden

Transcatheter Heart Valve Replacement Market Analysis

The Transcatheter Heart Valve Replacement Market is projected to grow from US$ 7.1 billion in 2025 to US$ 24.07 billion by 2034, registering a CAGR of 14.53% during the forecast period from 2026 to 2034. Market growth is primarily driven by the rising prevalence of heart valve disorders, particularly among the aging population. The increasing incidence of conditions such as aortic stenosis and mitral regurgitation is significantly boosting demand for transcatheter heart valve (THV) procedures, including transcatheter aortic valve replacement (TAVR), due to their minimally invasive nature and improved patient outcomes.

Transcatheter Heart Valve Replacement Industry Overview

Transcatheter Heart Valve Replacement (THVR) is a minimally invasive medical procedure used to replace damaged or diseased heart valves without performing traditional open-heart surgery. The procedure is commonly used to treat severe heart valve disorders such as aortic stenosis and mitral regurgitation, particularly in elderly patients or individuals considered high-risk for conventional surgery. During the procedure, a replacement valve is delivered to the heart through a catheter inserted into a blood vessel, usually through the leg or chest, allowing physicians to restore proper blood flow with less surgical trauma.

THVR procedures, including Transcatheter Aortic Valve Replacement (TAVR), are widely used because they offer several advantages such as shorter recovery time, reduced hospital stays, lower risk of complications, and faster return to normal activities. The popularity of THVR is increasing worldwide due to the rising prevalence of cardiovascular diseases, aging populations, and growing demand for minimally invasive treatment options. Technological advancements in valve design and imaging systems have further improved procedural safety and patient outcomes, supporting the rapid global adoption of transcatheter heart valve replacement therapies.

Request Sample Report:https://www.renub.com/request-sample-page.php?gturl=transcatheter-heart-valve-replacement-market-p.php

Transcatheter Heart Valve Replacement Product Launches Worldwide

·       Edwards Lifesciences launched the SAPIEN M3 Transcatheter Mitral Valve Replacement System in Europe in 2025 after receiving CE Mark approval. It became the world’s first approved transfemoral transcatheter mitral valve replacement system for patients with severe mitral regurgitation.

·       Edwards Lifesciences received U.S. FDA approval in 2025 for the SAPIEN M3 Mitral Valve Replacement System, marking the first transseptal transcatheter therapy approved for mitral regurgitation treatment.

·       Abbott introduced the Navitor Vision TAVI System in India in 2025 for severe aortic stenosis treatment. The device features enhanced visualization markers for more precise valve placement during minimally invasive TAVR procedures.

·       Medtronic received FDA approval in 2024 for its newest-generation Evolut FX+ TAVR System, designed to improve coronary access and procedural efficiency during transcatheter aortic valve replacement procedures.

·       Medtronic launched the Evolut FX+ Transcatheter Aortic Valve System in India in 2025, supporting minimally invasive treatment for patients with severe aortic stenosis while improving future coronary access capabilities.

·       Abbott expanded global commercialization of its Tendyne Transcatheter Mitral Valve Replacement System during 2024–2026 for patients suffering from severe mitral annular calcification and mitral valve dysfunction.

·       Abbott strengthened worldwide adoption of its Navitor TAVI System, enhancing minimally invasive treatment options for aortic stenosis patients globally.

·       Abbott received FDA approval in 2024 for the TriClip Transcatheter Tricuspid Valve Repair System, providing a minimally invasive treatment option for patients with severe tricuspid regurgitation.

·       JenaValve Technology accelerated development and commercialization activities for its transcatheter valve technologies, particularly for treating aortic regurgitation patients unsuitable for traditional surgery.

·       Boston Scientific announced a major strategic investment in MiRus LLC in 2026 to strengthen its transcatheter heart valve portfolio and re-enter the balloon-expandable TAVR market with next-generation valve technologies.

Top Countries with the Highest Number of Heart-Related Disease Cases Worldwide in 2025

• China – More than 330 million people are estimated to be living with cardiovascular and heart-related diseases, making China the largest global burden holder due to hypertension, smoking, and aging demographics.
• India – Approximately 320 million people are affected by cardiovascular diseases, driven by diabetes, obesity, hypertension, air pollution, and sedentary lifestyles.
• United States – Around 130 million adults are living with some form of cardiovascular disease, including coronary artery disease, heart failure, and hypertension.
• Russia – Estimated 40–45 million people suffer from heart-related diseases, with high mortality linked to smoking, alcohol use, and hypertension.
• Brazil – More than 30 million individuals are estimated to have cardiovascular disorders, fueled by obesity, diabetes, and urban lifestyle changes.
• Germany – Approximately 25–30 million people are affected by cardiovascular conditions, particularly among elderly populations.
• Japan – Around 20–25 million people are living with heart-related diseases, including hypertension, arrhythmia, and valvular disorders.
• Indonesia – More than 20 million individuals are estimated to suffer from cardiovascular diseases due to smoking prevalence and limited preventive care.
• Mexico – Approximately 15–20 million people are affected by heart-related diseases, largely associated with obesity and diabetes.
• United Kingdom – Around 7.6 million people are currently living with cardiovascular disease, including coronary heart disease and stroke-related conditions.

Growth Drivers for the Transcatheter Heart Valve Replacement Market

Rising Demand for Minimally Invasive Cardiac Procedures

The growing preference for minimally invasive procedures is significantly driving the expansion of the Transcatheter Heart Valve Replacement (THVR) market. Procedures such as Transcatheter Aortic Valve Replacement (TAVR) are increasingly favored over conventional open-heart surgeries because they provide multiple clinical and economic benefits, including faster recovery, reduced surgical trauma, shorter hospital stays, lower complication risks, and minimized post-operative discomfort. These advantages are especially valuable for elderly individuals and patients considered high-risk for traditional cardiac surgery, thereby broadening the patient population eligible for valve replacement therapies and supporting market growth. In addition, continuous technological advancements and regulatory approvals are accelerating the adoption of transcatheter therapies worldwide. Innovative devices designed for minimally invasive valve repair and replacement are improving procedural safety and patient outcomes. Advancements in catheter delivery systems, imaging technologies, and valve durability are strengthening physician confidence in catheter-based interventions. As clinical evidence supporting transcatheter procedures continues to grow, both healthcare providers and patients are increasingly choosing minimally invasive cardiovascular treatments, making them a major contributor to sustained THVR market expansion globally. In April 2024, Abbott Laboratories received FDA approval for its TriClip system, a transcatheter edge-to-edge repair technology designed to treat tricuspid regurgitation (TR). This innovative device enables a minimally invasive treatment option, avoiding the need for high-risk open-heart surgery. Clinical trial results demonstrated significant improvements in TR severity and overall patient quality of life, reinforcing the clinical value of transcatheter solutions.

Technological Advancements in Transcatheter Heart Valve Therapy

Technological advancements in transcatheter heart valve therapy are playing a major role in accelerating the growth of the Transcatheter Heart Valve Replacement (THVR) market by improving procedural efficiency, patient safety, and long-term treatment outcomes. Continuous innovations in device engineering, including advanced low-profile delivery systems, have enabled less invasive vascular access and greater procedural control, helping reduce surgical complications and enhance physician performance during valve implantation procedures. At the same time, improvements in valve design and structure have contributed to better durability, enhanced functionality, and reduced risks of complications such as paravalvular leakage. Advancements in imaging and procedural planning technologies are further supporting market expansion. Technologies such as three-dimensional computed tomography (3D CT), real-time imaging systems, and AI-assisted simulation tools are improving diagnostic accuracy, procedural planning, and device sizing precision. These innovations enable healthcare professionals to customize treatments according to individual patient anatomy, leading to higher procedural success rates and fewer post-operative complications. As a result, advanced transcatheter technologies continue to strengthen physician confidence and drive wider adoption of THVR procedures globally. Furthermore, next-generation valve materials are enhancing long-term outcomes and device usability. For instance, the SAPIEN 3 Ultra RESILIA valve by Edwards Lifesciences Corporation incorporates RESILIA bovine pericardial tissue designed to resist calcification, improve durability, and allow dry storage for better handling. Collectively, these technological advancements are broadening clinical applications, increasing physician confidence, and accelerating the adoption of transcatheter heart valve therapies globally.

Rising Prevalence of Heart Valve Diseases

The rising prevalence of heart valve disorders, particularly among the elderly population, is a key factor driving the growth of the Transcatheter Heart Valve (THV) procedures market. Heart conditions such as aortic stenosis and mitral regurgitation are becoming increasingly common worldwide due to aging demographics, extended life expectancy, and the growing incidence of cardiovascular risk factors including hypertension, obesity, and diabetes. This expanding patient population is creating strong demand for advanced minimally invasive treatment solutions such as transcatheter heart valve replacement therapies. In addition to the increasing disease burden, limited public awareness regarding heart valve disorders often leads to delayed diagnosis and disease progression. Many individuals, including high-risk elderly populations, remain unaware of the symptoms and severity associated with heart valve disease. The growing number of patients diagnosed with valve-related conditions and the associated mortality rates highlight the urgent need for improved early detection and effective treatment options. As awareness improves and disease prevalence continues to rise, healthcare providers are increasingly adopting transcatheter valve therapies to manage complex cardiac conditions more efficiently. This growing reliance on minimally invasive cardiovascular procedures is expected to support long-term expansion of the THV market globally.

Ask Analyst for Customization in Report:https://www.renub.com/request-sample-page.php?gturl=transcatheter-heart-valve-replacement-market-p.php

Country Analysis

United States Transcatheter Heart Valve Replacement Market

The United States Transcatheter Heart Valve Replacement (THVR) market is experiencing substantial growth due to the increasing prevalence of cardiovascular diseases and heart valve disorders across the country. Rising cases of heart attacks, hypertension, high cholesterol, obesity, and smoking-related cardiac conditions are significantly increasing the demand for advanced cardiac treatment solutions. A large portion of the population is exposed to one or more cardiovascular risk factors, contributing to the growing incidence of valve-related diseases that often require minimally invasive interventions such as transcatheter valve replacement procedures. In addition, the aging population and growing awareness regarding advanced cardiac care are further supporting market expansion. Healthcare providers are increasingly adopting THVR technologies because they offer reduced recovery times, lower surgical risks, and improved patient outcomes compared to traditional open-heart surgery. Strong healthcare infrastructure, favorable reimbursement policies, and continuous technological advancements are also contributing to the rapid growth of the THVR market in the United States.

Germany Transcatheter Heart Valve Replacement Market

The Germany Transcatheter Heart Valve Replacement (THVR) market is expanding steadily due to the increasing burden of cardiovascular diseases and the country’s rapidly aging population. Heart valve disorders such as aortic stenosis and mitral valve disease are becoming more common, creating strong demand for minimally invasive cardiac procedures including transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve replacement (TMVR). Germany is recognized as one of the leading European markets for transcatheter heart valve procedures, supported by advanced healthcare infrastructure, strong clinical expertise, and high adoption of innovative medical technologies. The growing preference for minimally invasive treatments over conventional open-heart surgeries is further accelerating market growth. In addition, favorable reimbursement systems, widespread availability of specialized cardiac centers, and increasing physician confidence in catheter-based therapies are supporting procedural adoption. Continuous focus on improving patient outcomes and reducing hospitalization periods is expected to further strengthen Germany’s THVR market growth.

China Transcatheter Heart Valve Replacement Market

The China Transcatheter Heart Valve Replacement (THVR) market is witnessing rapid growth due to the rising prevalence of cardiovascular diseases and the country’s expanding elderly population. Heart valve disorders, particularly aortic stenosis, are becoming increasingly common among older adults, creating strong demand for advanced minimally invasive therapies such as transcatheter aortic valve replacement (TAVR). Improving healthcare infrastructure, increasing healthcare expenditure, and greater awareness regarding cardiovascular disease management are supporting the adoption of transcatheter procedures across major hospitals and cardiac centers in China. The country is also benefiting from increased availability of both domestic and international transcatheter valve technologies, making advanced cardiac care more accessible to patients. In addition, ongoing physician training programs, growing clinical experience, and supportive healthcare initiatives are accelerating procedural adoption nationwide. As demand for minimally invasive cardiovascular treatments continues to increase, China is emerging as one of the fastest-growing markets in the global THVR industry.

Saudi Arabia Transcatheter Heart Valve Replacement Market

The Saudi Arabia Transcatheter Heart Valve Replacement (THVR) market is growing strongly due to increasing investments in healthcare infrastructure and rising adoption of advanced cardiovascular treatment technologies. The country is witnessing a growing burden of cardiovascular diseases, including heart valve disorders, largely driven by lifestyle changes, obesity, diabetes, and aging demographics. This increasing disease prevalence is generating higher demand for minimally invasive treatment options such as transcatheter aortic valve replacement (TAVR). Saudi Arabia is actively strengthening its cardiac care capabilities by expanding access to advanced medical technologies and improving specialized healthcare services. The adoption of next-generation transcatheter valve systems and increasing availability of advanced cardiac procedures are enhancing treatment outcomes for patients across the country. In addition, government healthcare modernization initiatives and rising awareness regarding minimally invasive cardiac interventions are supporting continued market expansion. These developments are positioning Saudi Arabia as an emerging growth market for THVR technologies in the Middle East.

Market Segments

Type

Transcatheter Aortic Valve Replacement

Transcatheter Mitral Valve Replacement

Transcatheter Pulmonary Valve Replacement

Material

·       Mechanical valves

·       Biological Valves

End-User

·       Hospitals

·       Ambulatory Surgical Centers

·       Others

Countries

North America

·       United States

·       Canada

Europe

·       France

·       Germany

·       Italy

·       Spain

·       United Kingdom

·       Belgium

·       Netherlands

·       Turkey

Asia Pacific

·       China

·       Japan

·       India

·       South Korea

·       Thailand

·       Malaysia

·       Indonesia

·       Australia

·       New Zealand

Latin America

·       Brazil

·       Mexico

·       Argentina

Middle East & Africa

·       Saudi Arabia

·       UAE

·       South Africa

All companies have been covered with 5 Viewpoints

·       Overviews

·       Key Person

·       Recent Developments

·       SWOT Analysis

·       Revenue Analysis

Key Players Analysis

·       Edwards Lifesciences

·       Abbott Laboratories

·       Medtronic Plc

·       LIVANOVA PLC

·       Boston Scientific Corporation

·       Artivion, Inc.

·       MicroPort Scientific Corporation

·       Venus Medtech (Hangzhou) Inc.

About the Company:

Renub Research is a Market Research and Consulting Company. We have more than 15 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.

Contact Us:

Company Name: Renub Research

Contact Person: Rajat Gupta

Phone No: (D) +91-120-421-9822 (IND)

Website: https://www.renub.com/

Email: rajat@renub.com